RxDoctor Payments Data

Stephanie Sekula-Smith

Medical · Floresville, TXNPI 1215169727

Payments from drug & device makers

$675in general payments, 2019–2025

Across 37 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$254
  • GSK$100
  • Pfizer$95
  • Amgen$89
  • Novartis$45
  • Bayer$40
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$66398%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC13$254
GSK6$100
Pfizer5$95
Amgen5$89
Novartis3$45
Bayer2$40
Merck2$35
Exact Sciences1$16

How this compares

$675 in reported general payments places this provider in the 50th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$63,790
Medicare patients
206
Services billed
2,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$69,467
TrulicityDulaglutide34$56,075
MounjaroTirzepatide47$55,868
EliquisApixaban39$44,589
MyrbetriqMirabegron50$31,837
JardianceEmpagliflozin26$22,247
JanuviaSitagliptin Phosphate20$20,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,616
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,903
XareltoRivaroxaban12$13,032
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$12,951
NovologInsulin Aspart18$2,996
LantusInsulin Glargine,hum.Rec.Anlog13$2,589
Levothyroxine Sodium294$2,344
Albuterol Sulfate HfaAlbuterol Sulfate57$2,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$254$111,94281 claims
PfizerEliquis$95$44,58939 claims
MerckJanuvia$35$20,46420 claims
GSKTrelegy Ellipta$100$15,61615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,490 medical providers in Texas.

Other medical in Floresville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →